Positive staining results in all 21 patients and 98.5% of samples from the patients (64 out of 65; negative staining, 1 sample, 1.5%; '1+', 15 samples, 23.1%; '2+', 17 samples, 26.2%, '3+', 28 samples, 43.1%; '4+', 4 samples, 6.2%) confirmed that EDB-FN may be useful as a cancer diagnostic biomarker in GBM. Here, FN1 is linked to glioblastoma.